NEWS & BLOG
Stay up to date with the latest news and updates from KCNQ2 Cure.
KCNQ2-Related Epilepsy ICD-10 Codes Approved!
What is an ICD-10 Code? Developed by the World Health Organization (WHO), this is the tenth version of the International Classification of Diseases (ICD), known as ICD-10. It is a…
All that Jazz: Success of the 2024 New Horizons in Science Dinner
A night of jazz and jubilation in Melbourne at the fifth KCNQ2 Cure New Horizons in Science Dinner on April 11th. Volunteers decked out in New Orleans masks transformed host…
Picture Perfect
It takes so much more energy When you love and live with someone who has a rare condition like KCNQ2, the day-to-day grind can feel overwhelming. How do you keep…
How my daughter’s medical history is a Tool Towards a CURE
My daughter Ella was only a month old when the neurologist at the third hospital she was sent to that month said, “Just go home and love her. We don’t…
Find Your Tribe
When tragedy strikes and your world is turned upside down, how do you start to recover? Who do you turn to for advice, reassurance, support? Here, KCNQ2 mum Claire Audibert…
KCNQ2 Cure and Invitae/Ciitizen partner on new observational study
The KCNQ2 Cure Alliance is excited to announce that we have partnered with Invitae Ciitizen to develop an Observational Study for patients affected by KCNQ2-DEE. Invitae Ciitizen has developed an…
Carlo’s Story
It was back in 1843 that Charles Dickens penned what would become the immortal Yuletide tale, A Christmas Carol. The miser Scrooge learns the true meaning of Christmas when he…
Gold Stars
A huge shout out to all our friends in the KCNQ2 Community for making the 2021 KCNQ2 Cure Virtual Summit such a smashing success. We are thrilled so many of…
A Focus on Food
Here at KCNQ2 Cure, especially during COVID-19, we find ourselves thinking a lot about food. Searching for new recipes. Recently, I caught up with a friend Down Under who has…
KCNQ2-DEE Clinical Trial
Xenon Pharmaceuticals is currently developing XEN496, which is a proprietary pediatric formulation of the active ingredient ezogabine, for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Ezogabine was previously…
